The Therapeutic Approach for Relapsed CML

Video

The Therapeutic Approach for Relapsed CML

A Patient With Relapsed CML and Comorbidities

December 2015

  • A 64-year-old male presented to his PCP with symptoms of fever, LUQ pain, and severe fatigue.
  • PMHx:
    • 2012: fainting associated with Long QT syndrome managed on propranolol.
    • 2014: stage 3 kidney disease (GFR; 45 mL/min)
    • 2014: NSCLC, stage IIA squamous histology treated with resection and chemoradiotherapy, pleural effusion managed with thoracentesis
  • PE: spleen palpable 1.5 inches below costal margin
  • CBC:
    • WBCs, 172,000/μL (metamyelocytes, 3%; myelocytes, 6%; basophils, 6%; blasts, 2%;
    • HCT, 30%
    • Platelets, 536,000/μL
    • Hb, 9.9 g/dL
  • Bone marrow biopsy: Ph+ in 20/20 metaphases
  • Q-PCR; BCR-ABL1/ABL1 ratio, 90%
  • The patient was started on therapy with imatinib 400 mg

  • March 2015:BCR-ABL1, 10% Q-PCR
  • June 2015:BCR-ABL1, 6% Q-PCR
  • September 2015:BCR-ABL1, 9% Q-PCR

December 2016:

  • BCR-ABL1, 15% Q-PCR
  • Bone marrow biopsy: Ph+ in 10/20 metaphases
  • Genetic testing was negative for known TKI resistance mutations
  • CBC normal count
Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
Related Content